This study found that non-bleeding adverse events associated with NOACs affect multiple organ systems, emphasizing the importance of clinical vigilance. Specific NOACs like dabigatran, apixaban, edoxaban, and rivaroxaban were linked to distinct adverse reactions, including metabolic imbalances, thyroid disorders, and menstrual irregularities.
25 citations
,
December 2005 in “Molecular Genetics and Metabolism” This study reports that riboflavin may increase enzymatic activity in a GCDH-deficient patient with specific mutations, but doesn't fully normalize urinary organic acid levels.
127 citations
,
June 2008 in “British Journal of Clinical Pharmacology” This study supports the conclusion that the hormetic dose-response model is the most prevalent and fundamental model in biological and biomedical sciences, applicable to a wide range of clinical conditions.
This review examines complex regional pain syndrome (CRPS I) mechanisms, including immune dysregulation and psychological factors, but reports no new clinical results; the authors highlight potential diagnostic refinements.
89 citations
,
January 2020 in “PubMed” This review discusses biotinidase deficiency, noting that biotin treatment from birth can prevent symptoms, but acknowledges the complexity and need for further understanding due to late-onset cases with varied clinical findings.